Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1.]
J.N. George.
Platelets.
Lancet, (2000), 355 pp. 1.531-1.539
[3.]
Z.M. Ruggeri.
Old concepts and new developments in the study of platelet aggregation.
J Clin Invest, (2001), 105 pp. 699-701
[4.]
Antiplatelet Trialists Collaboration.
Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients.
Br Med J, (1994), 308 pp. 81-106
[5.]
C. Patrono, B. Coller, J.E. Dalen, G.A. Fitzgeral, V. Fuster, M. Gent, et al.
Platelet active drugs. The relationship among dose, effectiveness, and side effects.
Chest, (2001), 119 pp. 39S-63S
[6.]
J.S. Bennett, S. Mousa.
Platelet function inhibitors in the year 2000.
Thromb Haemost, (2001), 85 pp. 395-400
[8.]
The SALT collaborative Group.
Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events.
Lancet, (1991), 338 pp. 1.345-1.361
[9.]
The Dutch TIA trial Study Group.
A comparison of two doses of aspirin (30 mg vs 283 mg in patients after transient ischemic attack or minor ischemic stroke.
N Engl J Med, (1991), 325 pp. 1.261-1.266
[10.]
C. Patrono.
Aspirin as an antiplatelet drug.
N Engl J Med, (1994), 330 pp. 1.287-1.294
[11.]
A. Sczeklik, M. Krzanowski, P. Gora, J. Radwan.
Antiplatelet drugs and generation of thrombin in clotting blood.
Blood, (1992), 80 pp. 2.006-2.011
[12.]
F. Cipollone, P. Patrignani, A. Creco, M.R. Panara, R. Padovano, F. Cuccurullo, et al.
Differential suppresion of thromboxane byosynthesis by indobufen and aspirin in patients with unstable angina.
Circulation, (1997), 96 pp. 1.109-1.116
[13.]
L. Plaza, L. López-Bescós, Jadraque Martín, E. Alegría, J.M. Cruz Fernández, J.A. Ruipérez, et al.
Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: results of a spanish multicentre trial.
Cardiology, (1993), 82 pp. 388-398
[15.]
P.W. Serruys, W. Rutsch, G.R. Heyndrick, N. Dauchin, E.G. Mast, W. Wijns, et al.
Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2 receptor blockade: a randomized, double blind, placebo-controlled trial.
Circulation, (1991), 84 pp. 1.568-1.580
[16.]
The RAPT Investigators.
Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and Thromboxane A2/prostaglandin endoperoxide receptor antagonist versus aspirin as adjunct to hrombolysis in patients with acute myocardial infarction. The ridogrel versus Aspirin Patency Trial (RAPT).
Circulation, (1994), 89 pp. 588-595
[17.]
G.A. Fitzgerald.
Dipyridamole.
N Engl J Med, (1987), 316 pp. 1.247-1.257
[18.]
ESPS 2-Group.
European stroke prevention study: 2. Efficacy and safety data.
J Neurol Sci, (1997), 151 pp. S1-S77
[19.]
J.M. Herbert, A. Lemat, M. Samama, J.P. Maffrand.
The antiaggregating and antithrombotic activity of ticlopidine.
Thromb Haemost, (1996), 76 pp. 94-98
[20.]
M.J. Quinn, D.J. Fitzgerald.
Ticlopidine and clopidogrel.
Circulation, (1999), 100 pp. 1.667-1.672
[21.]
E.J. Topol, T.V. Byzova, E.F. Plow.
Platelet IIb/IIIa blockers.
Lancet, (1999), 353 pp. 227-231
[22.]
J.J. Ferguson, M. Zaqqa.
Platelet glycoprotein IIb/IIIa receptor antagonists. Current concepts and future directions.
Drugs, (1999), 58 pp. 965-982
[23.]
M. Sitges, X. Bosch, G. Sanz.
Eficacia de los bloqueadores de los receptores plaquetarios IIb/IIIa en los síndromes coronarios agudos.
Rev Esp Cardiol, (2000), 53 pp. 422-439
[24.]
R.H. Foster, L.R. Wiseman.
Abciximab. An updated review of its use in ischemic heart disease.
Drugs, (1998), 56 pp. 629-665
[25.]
A. Meijer, F.W.A. Verheugt, C.J.P.J. Weter, K.L. Lie, J.M.J. van der Pol, M.J. van Eenige.
Aspirin versus coumadin in the prevention of reocclusion and recurrent ischaemia after succesful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study.
Circulation, (1993), 87 pp. 1.524-1.530
[26.]
H.D. White, J.K. French, A.W. Hamer, M.A. Brown, B.F. Williams, J.A. Ormiston, et al.
Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy.
J Am Coll Cardiol, (1995), 25 pp. 218-223
[27.]
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2.
Lancet, (1988), 2 pp. 349-360
[28.]
International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both or neither among 19435 patients with acute ischemic stroke.
Lancet, (1997), 349 pp. 1.569-1.581
[29.]
CAST (Chinese Acute Stroke Trial) Collaborative Group.
CAST: randomized placebo-controlled trial of early aspirin use in 20000 patients with acute ischaemic stroke.
Lancet, (1997), 349 pp. 1.641-1.649
[30.]
Z. Chem, P. Sandercock, H. Pau, C. Counsell, R. Collins, L. Liu, et al.
Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial.
Stroke, (2000), 31 pp. 1.240-1.249
[31.]
D.L. Bhatt, D.P. Chew, A.T. Hirsch, P.A. Ringleb, W. Hacke, E.J. Topol.
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.
Circulation, (2001), 103 pp. 363-368
[32.]
A. Oler, M.A. Wholley, J. Oler, D. Grady.
Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a metaanalysis.
JAMA, (1996), 276 pp. 811-815
[33.]
C.W. Hamm, C. Heeschen, B. Goldman, A. Vahanian, J. Adgey, C. Macaya, et al.
Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels.
N Engl J Med, (1999), 340 pp. 1.623-1.629
[34.]
D.L. Bhatt, E.J. Topol.
Current role of platelets glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
J Am Med Assoc, (2000), 284 pp. 1.549-1.558
[35.]
A.M. Lincoff, R.M. Califf, E.J. Topol.
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
J Am Coll Cardiol, (2000), 35 pp. 1.103-1.105
[36.]
J.H. Ip, V. Fuster, D. Israel, L. Badimon, J. Badimon, J.H. Chesebro.
The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty.
J Am Coll Cardiol, (1991), 17 pp. 77B-88B
[37.]
E.J. Topol, R.M. Califf, H.I. Weismann, S.G. Ellis, J.E. Tcheng, S. Worley, et al.
on behalf of the EPIC investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months.
Lancet, (1994), 343 pp. 881-886
[38.]
H.J. Rupprecht, H. Darius, U. Borkowski, T. Voigtlandert, B. Nowak, S. Genth, et al.
Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation.
Circulation, (1998), 97 pp. 1.046-1.052
[39.]
The EPISTENT Investigators.
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade.
Lancet, (1998), 352 pp. 87-92
[40.]
I. Moussa, M. Oetgen, G. Roubin, A. Colombo, X. Wang, S. Iyer, et al.
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.
Circulation, (1999), 99 pp. 2.364-2.366
[41.]
A.M. Lincoff, R.M. Califf, D.J. Moliterno, G. Ellis, J. Ducas, J.H. Kramer, for the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators, et al.
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors.
N Engl J Med, (1999), 341 pp. 319-327
[42.]
The SPAF III. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin. Stroke prevention in atrial fibrillation III study.
JAMA, (1998), 279 pp. 1.273-1.277
[43.]
CAPRIE Steering Committee. A Randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE).
Lancet, (1996), 348 pp. 1.329-1.339
[44.]
D.W. Taylor, H.J.M. Barnett, R.B. Haynes, G.G. Fergurson, D.L. Sackett, K.E. Thorpe, for the ASA and Carotid Endarterectomy (ACE) Trial Collaborators, et al.
Low-dose and highdose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised trial.
Lancet, (1999), 353 pp. 2.179-2.184
[45.]
F. Balsano, F. Violi, and the ADEP group: Effect of picotamide on the clinical progression of peripheral vascular disease: a double-blind placebo-controlled study.
Circulation, (1993), 87 pp. 1.563-1.569
[46.]
R. Sreedhara, J. Himmelfarb, J.M. Lazarus, R.M. Hakim.
Antiplatelet therapy in graft thrombosis: results of a prospective randomized double-blind study.
Kidney Int, (1994), 45 pp. 1.477-1.483
[47.]
EDTRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14.
J Am Med Assoc, (1992), 268 pp. 1.292-1.300
[48.]
The Steering Committee of the Physicians Health Study. Research Group Preliminary Report: findings from the aspirin component of the ongoing Physicians Health Study.
N Engl J Med, (1988), 318 pp. 362-364
[49.]
R. Peto, R. Gray, R. Collins, K. Wheatley, C. Hennekens, K. Jamrozik, et al.
Randomised trial of prophylactic daily aspirin in British male doctors.
Br Med J, (1988), 296 pp. 313-316
[50.]
J.A. Manson, M.J. Stampfer, G.A. Colditz, W.C. Willet, B. Rosner, F.E. Speizer, et al.
A prospective study of aspirin use and primary prevention of cardiovascular disease in women.
J Am Med Assoc, (1991), 266 pp. 521-527
[51.]
H.J.M. Barnett, M. Koste, H. Meldrum, M. Eliasziw.
Aspirin dose in stroke prevention. Beautiful hypothesis slain by ugly facts.
Stroke, (1997), 27 pp. 588-592
[52.]
Consensus conference on medical management of stroke.
Br J Haematol, (1998), 102 pp. 1.107-1.113
[53.]
M.B. Leon, D.S. Baim, J.J. Popma, P.C. Gordon, D.E. Cutlip, K.L. Kalon, et al.
A clinical trial comparing three antithrombotic regimens after coronary artery stenting.
N Engl J Med, (1998), 339 pp. 1.665-1.671
[54.]
CURE Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale design and baseline characteristics including a metaanalysis of the effects of thienopyridines in vascular disease.
Eur Heart J, (2000), 21 pp. 2.033-2.041
[55.]
Second Chinese Cardiac Study (CCS-2) Collaborative Group. Rationale design and organization of the second chinese Cardiac Study (CCS-2): a randomised trial of clopidogrel plus aspirin and of metoprolol among patients with suspected acute myocardial infarction.
J Cardiovasc Risk, (2000), 7 pp. 3.435-3.441
[56.]
J.E. Tcheng.
Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC IMPACT II RESTORE and EPILOG trials into perspective.
Am J Cardiol, (1996), 78 pp. 35-40
[57.]
D.F. Kong, R.M. Califf, D.P. Miller, D.J. Moliterno, D. White, R.A. Harrington, et al.
Clinical outcome of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.
Circulation, (1998), 98 pp. 2.829-2.835
[58.]
C.L. Bennet, J.M. Connors, J.M. Carwile, J.L. Moake, W.R. Bell, S.R. Tarantolo, et al.
Thrombotic thrombocytopenic purpura associated with clopidogrel.
N Engl J Med, (2000), 342 pp. 1.773-1.777
[59.]
H. Dasgupta, J.C. Blankenship, G.C. Wood, C.M. Frey, S.L. Demko, F.J. Menapace.
Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
Am Heart J, (2000), 140 pp. 206-211
[60.]
G. Montalecot, V. Polle, J.P. Collet, P. Leprince, A. Bellanger, I. Gandjbakhch, et al.
Low molecular weight heparin after mechanical heart valve replacement.
Curculation, (2000), 101 pp. 1.083-1.086
Copyright ©
2001. Elsevier España, S.L.. Todos los derechos reservados
